This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tobert, J. A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Rev. Drug Disc. 2, 517–526 (2003).
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo controlled trial. Lancet 360, 7–22 (2002).
Sever, P. S. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149–1158 (2003).
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002).
Watanabe, M. et al. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptonates, a novel series of HMG-CoA reductase inhibitors. Bioorg. Med. Chem. 5, 437–444 (1997).
FDA Drug Approvals List [online] (cited 26 Aug 2003). <http://www.fda.gov/cder/foi/label/2003/21366_crestor_lbl.pdf> (2003).
Jones, P. H. et al. for the STELLAR study group. Statin therapies for elevated lipid levels compared across dose ranges to rosuvastatin: low-density lipoprotein cholesterol and high density lipoprotein cholesterol results. J. Am. Coll. Cardiol. 92, 152–160 (2003).
Earl, J. & Kirkpatrick, P. Ezetimibe. Nature Rev. Drug Disc. 2, 97–98 (2003).
Lue, T. F. Erectile dysfunction. N. Engl. J. Med. 342, 1802–1813 (2000).
NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 270, 83–90 (1993).
Rotella, D. P. Phosphodiesterase 5 inhibitors: current status and potential applications. Nature Rev. Drug Disc. 1, 674–682 (2002).
Terrett, N. K. et al. Sildenafil (Viagra), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg. Med. Chem. Lett. 6, 1819–1824 (1996).
Haning, H. et al. Imidazo[5,1-f][1,2,4]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors. Bioorg. Med. Chem. Lett. 12, 865–868 (2002).
Daugan, A. et al. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1:5,6,11,11a-tetrahydro-1Himidazo[1′,5′:1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues. J. Med. Chem. 46, 4525–4532 (2003).
Daugan, A. et al. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12ahexahydropyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione analogues. J. Med. Chem. 46, 4533–4542 (2003).
FDA Drug Approvals List [online] (cited 10 Feb 2004) <http://www.fda.gov/cder/foi/label/2003/021400lbl.pdf> (2003).
FDA Drug Approvals List [online] (cited 10 Feb 2004) <http://www.fda.gov/cder/foi/label/2003/021368lbl.pdf> (2003).
Rajfer, J. et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N. Engl. J. Med. 326, 90–94 (1992).
Additional information
Authorship This section was authored by Jeremy Quirk, Mark Thornton, Katherine Neumeyer and Peter Kirkpatrick, and includes material first published in Nature Reviews Drug Discovery. Jeremy Quirk and Mark Thornton are at Decision Resources Intl, 50–51 Russell Square, London, WC1B 4HQ, UK. Katherine Neumeyer is at Decision Resources Inc., 260 Charles Street, Waltham, Massachusetts 02453, USA. Peter Kirkpatrick is at Nature Reviews Drug Discovery.
Rights and permissions
About this article
Cite this article
Cardiology and vascular disoders. Nat Rev Drug Discov 3 (Suppl 7), S13–S17 (2004). https://doi.org/10.1038/nrd1407
Issue Date:
DOI: https://doi.org/10.1038/nrd1407